Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970804 | 0.96 | CNR2 (0.40) | DRD4SIGMAR1DRD3TMEM97CNR2 | |
| SCHEMBL19982564 | 0.94 | SLC2A1 (0.42) | DRD4SIGMAR1DRD3TMEM97BCHE | |
| SCHEMBL19982583 | 0.92 | SLC2A1 (0.42) | DRD4SIGMAR1DRD3TMEM97CNR2 | |
| SCHEMBL19986770 | 0.92 | BCHE (0.45) | BCHEACHECHEK2 | |
| SCHEMBL19970747 | 0.91 | DRD4 (0.45) | DRD4SIGMAR1DRD3TMEM97CNR2 | |
| SCHEMBL19970810 | 0.90 | CHEK2 (0.41) | BCHEACHESLC2A1CHEK2AKT1 | |
| SCHEMBL19970723 | 0.89 | CHEK2 (0.43) | BCHEACHECHEK2 | |
| SCHEMBL19982610 | 0.88 | SLC2A1 (0.42) | DRD4SIGMAR1DRD3TMEM97CNR2 | |
| SCHEMBL19982657 | 0.88 | DRD4 (0.42) | DRD4SIGMAR1DRD3TMEM97CNR2 | |
| SCHEMBL19970805 | 0.88 | CYP1A2 (0.41) | BCHEACHECHEK2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-25 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | UNIVERSITE D'ORLEANS (FR) | 2021-09-23 | — | — | US | disclosed |
| WO-2018050771-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-22 | — | — | WO | disclosed |
| EP-3296297-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292350-A1 | BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION | FIP1L1, ZC3HAV1, MAVS | DRD4 3057/4885SIGMAR1 2624/4885DRD3 2942/4885 |
| US-11479571-B2 | Benzimidazol derivatives for treating filovirus infection | FIP1L1, ZC3HAV1, MAVS | DRD4 3057/4885SIGMAR1 2624/4885DRD3 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.